BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37874915)

  • 1. Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms.
    Durham BH; Hershkovitz-Rokah O; Abdel-Wahab O; Yabe M; Chung YR; Itchaki G; Ben-Sasson M; Asher-Guz VA; Groshar D; Doe-Tetteh SA; Alano T; Solit DB; Shpilberg O; Diamond EL; Mazor RD
    Blood Adv; 2023 Dec; 7(23):7319-7328. PubMed ID: 37874915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
    Diamond EL; Durham BH; Haroche J; Yao Z; Ma J; Parikh SA; Wang Z; Choi J; Kim E; Cohen-Aubart F; Lee SC; Gao Y; Micol JB; Campbell P; Walsh MP; Sylvester B; Dolgalev I; Aminova O; Heguy A; Zappile P; Nakitandwe J; Ganzel C; Dalton JD; Ellison DW; Estrada-Veras J; Lacouture M; Gahl WA; Stephens PJ; Miller VA; Ross JS; Ali SM; Briggs SR; Fasan O; Block J; Héritier S; Donadieu J; Solit DB; Hyman DM; Baselga J; Janku F; Taylor BS; Park CY; Amoura Z; Dogan A; Emile JF; Rosen N; Gruber TA; Abdel-Wahab O
    Cancer Discov; 2016 Feb; 6(2):154-65. PubMed ID: 26566875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histiocytic neoplasms in the era of personalized genomic medicine.
    Durham BH; Diamond EL; Abdel-Wahab O
    Curr Opin Hematol; 2016 Jul; 23(4):416-25. PubMed ID: 27101528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells.
    Durham BH; Roos-Weil D; Baillou C; Cohen-Aubart F; Yoshimi A; Miyara M; Papo M; Hélias-Rodzewicz Z; Terrones N; Ozkaya N; Dogan A; Rampal R; Urbain F; Le Fèvre L; Diamond EL; Park CY; Papo T; Charlotte F; Gorochov G; Taly V; Bernard OA; Amoura Z; Abdel-Wahab O; Lemoine FM; Haroche J; Emile JF
    Blood; 2017 Jul; 130(2):176-180. PubMed ID: 28566492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders.
    Allen CE; Parsons DW
    Hematology Am Soc Hematol Educ Program; 2015; 2015():559-64. PubMed ID: 26637772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.
    Li Q
    J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders.
    Wilk CM; Cathomas F; Török O; Le Berichel J; Park MD; Bigenwald C; Heaton GR; Hamon P; Troncoso L; Scull BP; Dangoor D; Silvin A; Fleischmann R; Belabed M; Lin H; Merad Taouli E; Boettcher S; Li L; Aubry A; Manz MG; Kofler JK; Yue Z; Lira SA; Ginhoux F; Crary JF; McClain KL; Picarsic JL; Russo SJ; Allen CE; Merad M
    Immunity; 2023 Dec; 56(12):2790-2802.e6. PubMed ID: 38091952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adult xanthogranuloma with a small portion of BRAF
    Ishikawa M; Endo Y; Uehara A; Suto M; Yasuda M; Motegi SI; Ishikawa O
    J Dermatol; 2019 Feb; 46(2):161-165. PubMed ID: 30536719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards molecular-based management of childhood Langerhans cell histiocytosis.
    Héritier S; Emile JF; Hélias-Rodzewicz Z; Donadieu J
    Arch Pediatr; 2019 Jul; 26(5):301-307. PubMed ID: 31281037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
    McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
    Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Langerhans cell histiocytosis: Version 2021.
    Gulati N; Allen CE
    Hematol Oncol; 2021 Jun; 39 Suppl 1(Suppl 1):15-23. PubMed ID: 34105821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci.
    Egeler RM; Katewa S; Leenen PJ; Beverley P; Collin M; Ginhoux F; Arceci RJ; Rollins BJ;
    Pediatr Blood Cancer; 2016 Oct; 63(10):1704-12. PubMed ID: 27314817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
    Kemps PG; Zondag TCE; Arnardóttir HB; Solleveld-Westerink N; Borst J; Steenwijk EC; van Egmond D; Swennenhuis JF; Stelloo E; Trambusti I; Verdijk RM; van Noesel CJM; Cleven AHG; Scheijde-Vermeulen MA; Koudijs MJ; Krsková L; Hawkins C; Egeler RM; Brok J; von Bahr Greenwood T; Svojgr K; Beishuizen A; van Laar JAM; Pötschger U; Hutter C; Sieni E; Minkov M; Abla O; van Wezel T; van den Bos C; van Halteren AGS
    Blood Adv; 2023 Feb; 7(4):664-679. PubMed ID: 36083130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitogen-activating protein kinase pathway alterations in Langerhans cell histiocytosis.
    Jouenne F; Benattia A; Tazi A
    Curr Opin Oncol; 2021 Mar; 33(2):101-109. PubMed ID: 33315630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.
    Chakraborty R; Hampton OA; Shen X; Simko SJ; Shih A; Abhyankar H; Lim KP; Covington KR; Trevino L; Dewal N; Muzny DM; Doddapaneni H; Hu J; Wang L; Lupo PJ; Hicks MJ; Bonilla DL; Dwyer KC; Berres ML; Poulikakos PI; Merad M; McClain KL; Wheeler DA; Allen CE; Parsons DW
    Blood; 2014 Nov; 124(19):3007-15. PubMed ID: 25202140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow-derived myeloid progenitors as driver mutation carriers in high- and low-risk Langerhans cell histiocytosis.
    Xiao Y; van Halteren AGS; Lei X; Borst J; Steenwijk E; de Wit T; Grabowska J; Voogd R; Kemps P; Picarsic J; van den Bos C; Borst J
    Blood; 2020 Nov; 136(19):2188-2199. PubMed ID: 32750121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer.
    Lin JJ; Ritterhouse LL; Ali SM; Bailey M; Schrock AB; Gainor JF; Ferris LA; Mino-Kenudson M; Miller VA; Iafrate AJ; Lennerz JK; Shaw AT
    J Thorac Oncol; 2017 May; 12(5):872-877. PubMed ID: 28088512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vemurafenib acts as a molecular on-off switch governing systemic inflammation in Langerhans cell histiocytosis.
    Eder SK; Schwentner R; Ben Soussia P; Abagnale G; Attarbaschi A; Minkov M; Halbritter F; Hutter C
    Blood Adv; 2022 Feb; 6(3):970-975. PubMed ID: 34619771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAF/MEK/extracellular signal-related kinase pathway suppresses dendritic cell migration and traps dendritic cells in Langerhans cell histiocytosis lesions.
    Hogstad B; Berres ML; Chakraborty R; Tang J; Bigenwald C; Serasinghe M; Lim KPH; Lin H; Man TK; Remark R; Baxter S; Kana V; Jordan S; Karoulia Z; Kwan WH; Leboeuf M; Brandt E; Salmon H; McClain K; Poulikakos P; Chipuk J; Mulder WJM; Allen CE; Merad M
    J Exp Med; 2018 Jan; 215(1):319-336. PubMed ID: 29263218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An overview of histiocytosis].
    Tojo A
    Rinsho Ketsueki; 2022; 63(5):363-367. PubMed ID: 35662158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.